{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:18:09Z","timestamp":1787494689281,"version":"build-2736575974"},"reference-count":42,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Amgen Ltd."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,9,17]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Patients with multiple myeloma (MM) experience significant delays in diagnosis due to non-specific symptomatology. The aim of this study was to characterise the frequency and timing of clinical features in the primary care setting prior to MM diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Population-based cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Electronic health records data of approximately 17\u2009million patients (2006\u20132016) within the UK Clinical Practice Research Datalink.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients aged \u226518 years with newly diagnosed MM (NDMM), no history of solid tumours and \u22652 years registration in a primary care practice prior to MM diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Clinical features and symptoms including bone pain, skeletal-related events (SREs), investigation and confirmation of MM diagnostic CRAB criteria (hyperCalcaemia, Renal impairment, Anaemia, Bone lesions) during the 2 years prior to MM diagnosis; time between symptom manifestation and\/or relevant investigation and diagnosis of MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 2646 patients with NDMM, 47.5% had a bone pain record during the 2-year period prior to MM diagnosis, mainly affecting the back. Regardless of baseline bone pain, investigations for serum calcium level were used in 36.4% of patients prior to MM diagnosis, followed by haemoglobin (65.6%) or renal function (74.1%). Median (Q1, Q3) time from first-recorded bone pain to MM diagnosis was 220 (80, 476) days. Median (Q1, Q3) time from first-recorded hypercalcaemia, renal impairment or anaemia to MM diagnosis was 23 (12, 46), 58 (17, 254) and 73 days (28, 232), respectively. An imaging investigation or referral for imaging was recorded for 60.0% of patients with bone pain\/SRE and 32% without.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nearly half of patients diagnosed with NDMM presented with bone pain approximately 7\u2009months prior to MM diagnosis. Investigations to evaluate all CRAB criteria, including targeted imaging, were underused. Early recognition of myeloma clinical features and optimised use of investigations in primary care may potentially expedite MM diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-052759","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T03:45:22Z","timestamp":1650512722000},"page":"e052759","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-5867","authenticated-orcid":false,"given":"Anouchka","family":"Seesaghur","sequence":"first","affiliation":[{"name":"Center for Observational Research (CfOR), Amgen Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Petruski-Ivleva","sequence":"additional","affiliation":[{"name":"Science, Aetion, Inc, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria Louise","family":"Banks","sequence":"additional","affiliation":[{"name":"Center for Observational Research (CfOR), Amgen Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn Ruoyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Science, Aetion, Inc, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Abbasi","sequence":"additional","affiliation":[{"name":"Center for Observational Research (CfOR), Amgen Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Neasham","sequence":"additional","affiliation":[{"name":"Center for Observational Research (CfOR), Amgen Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"2025121509234871000_11.10.e052759.1","unstructured":"Cancer Research UK . Myeloma incidence statistics. Available: https:\/\/wwwcancerresearchukorg\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma\/incidence#heading-Zero [Accessed January 2021]."},{"key":"2025121509234871000_11.10.e052759.2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.304"},{"key":"2025121509234871000_11.10.e052759.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194788","article-title":"Myeloma: patient accounts of their pathways to diagnosis","volume":"13","author":"Howell","year":"2018","journal-title":"PLoS One"},{"key":"2025121509234871000_11.10.e052759.4","doi-asserted-by":"crossref","DOI":"10.1186\/2052-1839-13-9","article-title":"Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the haematological malignancy research network","volume":"13","author":"Howell","year":"2013","journal-title":"BMC Blood Disord"},{"key":"2025121509234871000_11.10.e052759.5","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp17X694169"},{"key":"2025121509234871000_11.10.e052759.6","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902741471"},{"key":"2025121509234871000_11.10.e052759.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70041-4"},{"key":"2025121509234871000_11.10.e052759.8","unstructured":"National Cancer Registration and Analysis Service (NCRAS) . Routes to diagnosis 2006-2015, 2017. Available: http:\/\/wwwncinorguk\/publications\/routes_to_diagnosis [Accessed December 2020]."},{"key":"2025121509234871000_11.10.e052759.9","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm077"},{"key":"2025121509234871000_11.10.e052759.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05867.x"},{"key":"2025121509234871000_11.10.e052759.11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/rheumatology\/kez127","article-title":"Testing and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures","volume":"58","author":"Nador","year":"2019","journal-title":"Rheumatology"},{"key":"2025121509234871000_11.10.e052759.12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082113","article-title":"Multiple myeloma associated bone disease","volume":"12","author":"Rasch","year":"2020","journal-title":"Cancers"},{"key":"2025121509234871000_11.10.e052759.13","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.408"},{"key":"2025121509234871000_11.10.e052759.14","unstructured":"Blood Cancer UK . The current STATs of blood cancer diagnosis in England: an end the delays campaign report. London: Bloodwise, 2019. https:\/\/mediabloodcancerorguk\/documents\/bloodwise-delayed-diagnosis-report_RIQgdp7pdf"},{"key":"2025121509234871000_11.10.e052759.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7953"},{"key":"2025121509234871000_11.10.e052759.16","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp15X683545"},{"key":"2025121509234871000_11.10.e052759.17","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025121509234871000_11.10.e052759.18","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(97)04248-7","article-title":"The UK general practice research database","volume":"350","author":"Walley","year":"1997","journal-title":"The Lancet"},{"key":"2025121509234871000_11.10.e052759.19","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3079"},{"key":"2025121509234871000_11.10.e052759.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6732.1092"},{"key":"2025121509234871000_11.10.e052759.21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/pds.5171","article-title":"Real-World reproducibility study characterizing patients newly diagnosed with multiple myeloma using clinical practice research Datalink, a UK-based electronic health records database","volume":"30","author":"Seesaghur","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121509234871000_11.10.e052759.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7901"},{"key":"2025121509234871000_11.10.e052759.23","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.329"},{"key":"2025121509234871000_11.10.e052759.24","unstructured":"National Institute for Health and Care Excellence (NICE) . Myeloma: diagnosis and management. NICE guideline [NG35], 2018. Available: https:\/\/wwwniceorguk\/guidance\/ng35\/chapter\/Recommendations#imaging-investigations [Accessed March 2021]."},{"key":"2025121509234871000_11.10.e052759.25","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2016.06.150393"},{"key":"2025121509234871000_11.10.e052759.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019758"},{"key":"2025121509234871000_11.10.e052759.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3557"},{"key":"2025121509234871000_11.10.e052759.28","unstructured":"GP . Half of GPs say patients harmed by delays to care during COVID-19 pandemic. Available: https:\/\/www.gponline.com\/half-gps-say-patients-harmed-delays-care-during-covid-19-pandemic\/article\/1697972 [Accessed January 2021]."},{"key":"2025121509234871000_11.10.e052759.29","unstructured":"NHS . NHS diagnostic waiting times and activity data. Available: https:\/\/wwwenglandnhsuk\/statistics\/wp-content\/uploads\/sites\/2\/2020\/11\/DWTA-Report-September-2020_1ME27pdf [Accessed January 2021]."},{"key":"2025121509234871000_11.10.e052759.30","unstructured":"UK Parliament . Written evidence submitted by myeloma UK (DEL0060).. Available: https:\/\/committeesparliamentuk\/writtenevidence\/2688\/html\/ [Accessed January 2021]."},{"key":"2025121509234871000_11.10.e052759.31","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp18X700193"},{"key":"2025121509234871000_11.10.e052759.32","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-019-0951-x"},{"key":"2025121509234871000_11.10.e052759.33","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14513"},{"key":"2025121509234871000_11.10.e052759.34","doi-asserted-by":"crossref","first-page":"100243","DOI":"10.1016\/j.jbo.2019.100243","article-title":"Unplanned admissions for patients with myeloma in the UK: low frequency but high costs","volume":"17","author":"Kolovos","year":"2019","journal-title":"J Bone Oncol"},{"key":"2025121509234871000_11.10.e052759.35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034244"},{"key":"2025121509234871000_11.10.e052759.36","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-019-0951-x"},{"key":"2025121509234871000_11.10.e052759.37","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2020.0697"},{"key":"2025121509234871000_11.10.e052759.38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3855"},{"key":"2025121509234871000_11.10.e052759.39","unstructured":"NHS . NHS to introduce \u2018one stop shops\u2019 in the community for life saving checks, 2020. Available: https:\/\/www.england.nhs.uk\/2020\/10\/nhs-to-introduce-one-stop-shops-in-the-community-for-life-saving-checks\/ [Accessed January 2021]."},{"key":"2025121509234871000_11.10.e052759.40","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(20)30593-3","article-title":"A roadmap for the early detection and diagnosis of cancer","volume":"21","author":"Crosby","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025121509234871000_11.10.e052759.41","unstructured":"NHS . Nhs long term plan. Available: https:\/\/wwwlongtermplannhsuk\/online-version\/chapter-3-further-progress-on-care-quality-and-outcomes\/better-care-for-major-health-conditions\/cancer\/ [Accessed January 2021]."},{"key":"2025121509234871000_11.10.e052759.42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071596","article-title":"Bone Pain in Multiple Myeloma (BPMM)-A Protocol for a Prospective, Longitudinal, Observational Study","volume":"13","author":"Diaz-delCastillo","year":"2021","journal-title":"Cancers"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-052759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:24:02Z","timestamp":1765819442000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-052759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,6]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/bmjopen-2021-052759"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-052759","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}